Clinical Research Directory
Browse clinical research sites, groups, and studies.
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Sponsor: Assiut University
Summary
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
Official title: Potential Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease
Key Details
Gender
All
Age Range
20 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-08-10
Completion Date
2024-08-31
Last Updated
2024-08-16
Healthy Volunteers
Yes
Conditions
Interventions
Eplereone
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Locations (1)
Assiut University Heart Hospital
Asyut, Egypt